title: Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
abstract: Currently no standard treatment exists for patients with posttransplant lymphoproliferative disorders relapsed or refractory to chemotherapy after failure of reduction in immunosuppression. We have analyzed the effects of single-agent rituximab treatment in eight patients (seven adult, one pediatric) in this setting. Three patients had been salvaged with rituximab several times. In the seven adults, rituximab salvage therapy achieved complete remission (CR) in three patients (43%) and partial remission in one (14%). In the pediatric patient, a PR was obtained that could be reinduced on relapse with repeated administrations of rituximab. Patients achieving CR either remained in CR or were successfully salvaged again with single-agent rituximab. At a median follow-up of 69 months, median progression-free survival was 9 months and no relevant therapy-associated toxicity was observed. Single-agent rituximab salvage therapy is an effective treatment option in this setting of intensively pretreated patients, with virtually no therapy-associated toxicity.
authors.affiliation: Department of Hematology and Oncology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany. ralf.trappe@charite.de
authors.forename: Ralf U
authors.initials: RU
authors.lastname: Trappe
authors.forename: Sylvain
authors.initials: S
authors.lastname: Choquet
authors.forename: Petra
authors.initials: P
authors.lastname: Reinke
authors.forename: Martin
authors.initials: M
authors.lastname: Dreyling
authors.forename: Hans-Günther
authors.initials: HG
authors.lastname: Mergenthaler
authors.forename: Ulrich
authors.initials: U
authors.lastname: Jäger
authors.forename: Christian
authors.initials: C
authors.lastname: Kebelmann-Betzing
authors.forename: Sven
authors.initials: S
authors.lastname: Jonas
authors.forename: Hans
authors.initials: H
authors.lastname: Lehmkuhl
authors.forename: Ioannis
authors.initials: I
authors.lastname: Anagnostopoulos
authors.forename: Véronique
authors.initials: V
authors.lastname: Leblond
authors.forename: Roland
authors.initials: R
authors.lastname: Hetzer
authors.forename: Bernd
authors.initials: B
authors.lastname: Dörken
authors.forename: Hanno
authors.initials: H
authors.lastname: Riess
authors.forename: Stephan
authors.initials: S
authors.lastname: Oertel
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007165:Immunosuppression Therapy; D008232:Lymphoproliferative Disorders / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D016879:Salvage Therapy; D016019:Survival Analysis; D017741:Survivors; D017211:Treatment Failure; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone